This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PDE 4 Inhibitor

UCB SA

Drug Names(s): Phosphodiesterase 4 inhibitor

Deal Structure: The Celltech Group, the original developer of PDE 4, was acquired by UCB S.A. for approximately $1.9 billion on May 18th, 2004.

Partners: Merck & Co., Inc.


PDE 4 Inhibitor News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug